Coherus BioSciences Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Coherus BioSciences Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 06 Dec 2022 | Lorem |
| CMS’ Medicare Advantage step edits in Part B likely to have muted impact on biosimilar uptake due to influence of similar challenges with commercial plans, experts say | 16 Aug 2018 | Manasi Vaidya |
| Coherus BioScience’s Udenyca and CHS-1420 biosimilars for Amgen’s Neulasta and AbbVie’s Humira have market uptake concerns despite likely approvals, experts say | 14 Aug 2018 | Arafa Salam |
| J&J's motion to dismiss Pfizer’s biosimilar antitrust suit might shake up viability of exclusionary contracts if unsuccessful; granted motion could stifle innovation, experts say | 27 Mar 2018 | Shuan Sim,;Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward